Cocrystal Pharma Inc (COCP)

$1.98 -0.04 (-1.74%)
Market Cap 20.09M
Revenue (ttm) 0.00
Net Income (ttm) -17.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 24,000
Avg Vol 50,040
Day's Range N/A - N/A
Shares Out 10.17M
Stochastic %K 8%
Beta 1.53
Analysts Strong Sell
Price Target $8.33

Latest News on COCP

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Dec 31, 2024, 2:21 PM EST - 19 days ago

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Dec 31, 2024, 8:00 AM EST - 19 days ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 19, 2024, 4:05 PM EDT - 5 months ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Aug 15, 2024, 3:00 PM EDT - 5 months ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 13, 2024, 8:00 AM EDT - 8 months ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

May 1, 2024, 8:00 AM EDT - 9 months ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 28, 2024, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 19, 2024, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Mar 5, 2024, 8:30 AM EST - 11 months ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Dec 6, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 29, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 27, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 9, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 10, 2023, 8:30 AM EDT - 1 year ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Mar 22, 2023, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 26, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Jan 23, 2023, 9:00 AM EST - 2 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Dec 1, 2022, 4:05 PM EST - 2 years ago

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Nov 17, 2022, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Nov 1, 2022, 4:05 PM EDT - 2 years ago

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

Oct 26, 2022, 8:00 AM EDT - 2 years ago

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Oct 5, 2022, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Oct 3, 2022, 4:05 PM EDT - 2 years ago

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Aug 8, 2022, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

Aug 3, 2022, 9:00 AM EDT - 2 years ago

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

May 11, 2022, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

Apr 19, 2022, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

Apr 12, 2022, 11:08 AM EDT - 3 years ago

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

Apr 12, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

Mar 23, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

Mar 22, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

Mar 10, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

Jan 27, 2022, 12:22 PM EST - 3 years ago

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Jan 27, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Jan 6, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant

Dec 22, 2021, 11:43 AM EST - 3 years ago

Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant

Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

Dec 22, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets' Channelchek Virtual Roadshow

Dec 2, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets' Channelchek Virtual Roadshow

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

Dec 1, 2021, 4:05 PM EST - 3 years ago

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

Cocrystal Pharma's SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

Nov 8, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma's SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19

Nov 1, 2021, 7:24 PM EDT - 3 years ago

Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment

Nov 1, 2021, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

Oct 14, 2021, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

Oct 6, 2021, 8:49 AM EDT - 3 years ago

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

Cocrystal Pharma Stock Is Trading Higher After COVID-19 Candidate Shows Preclinical Activity Against Delta, Gamma Variants

Jul 29, 2021, 10:10 AM EDT - 3 years ago

Cocrystal Pharma Stock Is Trading Higher After COVID-19 Candidate Shows Preclinical Activity Against Delta, Gamma Variants

Cocrystal Joins Russell Microcap® Index

Jun 28, 2021, 8:00 AM EDT - 3 years ago

Cocrystal Joins Russell Microcap® Index

Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

Jun 23, 2021, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter